Dupilumab treatment in two patients with severe allergic contact dermatitis caused by sesquiterpene lactones
Abstract
I.F.R. has no conflicts of interest. L.S. has been a paid speaker for AbbVie, Eli Lilly, Novartis, and LEO Pharma, and has been a consultant or has served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, Almirall, and Sanofi. She has served as an investigator for AbbVie, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZenica, Eli Lilly, Novartis, Regeneron, and LEO Pharma, and has received research and educational grants from Novartis, Sanofi, Janssen Cilag, and LEO Pharma. C.Z. has served as an investigator for Pfizer, AbbVie, Regeneron, and LEO Pharma and received research and educational grants from Cellgene and Leo Pharma. J.P.T. has attended advisory boards for Sanofi-Genzyme, Eli Lilly & Co, Pfizer, Abbvie, and Union Therapeutics, and received speaker honorarium from LEO Pharma, Regeneron, Abbvie, and Sanofi-Genzyme, and has been an investigator for Sanofi-Genzyme, Eli Lilly & Co, LEO Pharma, Pfizer, and Abbvie.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There have been multiple reports demonstrating the effectiveness of dupilumab in the treatment of ACD.
“There have been multiple reports demonstrating the effectiveness of dupilumab in the treatment of ACD (eTable).[12][13][14][15][16][17][18][19][20]”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [19]
Findings from these studies show that dupilumab can improve recalcitrant dermatitis caused by a broad range of contact allergens, including nickel.
“The findings from these studies show that dupilumab can improve recalcitrant dermatitis caused by a broad range of contact allergens, including nickel.”
From Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing. (2022) · cites this paper as [19]
Cited by
Sorted by citations
Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing.
Johnson, H. (2022) · Current Psychiatry · doi:10.12788/cutis.0519 · Cited by 20 · see citing works
- Authors
- Ruge, I. F., Skov, L., Zachariae, C., & Thyssen, J. P.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Ruge, Iben Frier
- Venue
- Contact Dermatitis
- Publisher
- Wiley
- Published
- 2020-04-20
- Volume
- 83
- Issue
- 2
- Pages
- 137-139
- ISSN
- 0105-1873 (ISSN-L)
- 1600-0536
- OpenAlex
- W3014131789
- Cited by
- 23
- References
- 0
- Citations by year
- 2025: 5 · 2024: 5 · 2023: 3 · 2022: 5 · 2021: 5
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Contact Dermatitis (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Pharmacology › Drug-Induced Adverse Reactions
- Keywords
- dupilumab, allergic contact dermatitis, sesquiterpene lactones, biologic therapy
- MeSH terms
- Aged, Female, Humans, Immunologic Factors, Lactones, Male, Middle Aged, Sesquiterpenes, Dermatitis, Allergic Contact, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
